|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of AKT1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression increases secretion affects expression |
EXP ISO |
ceric oxide results in decreased expression of ALB protein ceric oxide results in increased secretion of ALB protein ceric oxide affects the expression of ALB mRNA |
CTD |
PMID:22072870 PMID:23726862 PMID:29463257 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of AP3D1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
ceric oxide results in increased expression of APAF1 protein |
CTD |
PMID:24987704 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
ceric oxide results in increased expression of BAX protein |
CTD |
PMID:24987704 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
ceric oxide results in decreased expression of BCL2 protein |
CTD |
PMID:24987704 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
EXP |
ceric oxide results in increased expression of BIRC5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
decreases expression |
EXP |
ceric oxide results in decreased expression of BRCA1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases expression |
ISO |
ceric oxide results in increased cleavage of CASP3 protein ceric oxide results in increased expression of CASP3 protein |
CTD |
PMID:24987704 PMID:26028148 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
affects expression |
ISO |
ceric oxide analog affects the expression of CASP7 mRNA |
CTD |
PMID:22960666 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
ceric oxide results in increased expression of CASP9 protein |
CTD |
PMID:24987704 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions affects expression |
ISO EXP |
ceric oxide results in decreased activity of CAT protein Acetylcysteine inhibits the reaction [ceric oxide results in decreased activity of CAT protein] ceric oxide affects the expression of CAT protein |
CTD |
PMID:20457660 PMID:23416263 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions increases expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in decreased expression of CCL11 mRNA; [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL11 protein; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of CCL11 mRNA] ceric oxide results in increased expression of CCL11 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
multiple interactions increases expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL17 mRNA ceric oxide results in increased expression of CCL17 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases secretion increases expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in decreased expression of CCL2 mRNA ceric oxide results in increased secretion of CCL2 protein ceric oxide results in increased expression of CCL2 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
multiple interactions affects expression |
ISO EXP |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL20 mRNA ceric oxide affects the expression of CCL20 mRNA |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL22 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl24 |
C-C motif chemokine ligand 24 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL24 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CCL26 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL3 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
ceric oxide results in increased expression of CCL7 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
increases expression |
EXP |
ceric oxide results in increased expression of CCR2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd177 |
CD177 molecule |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CD177 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
EXP |
ceric oxide results in decreased expression of CD40LG mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd63 |
Cd63 molecule |
increases expression |
ISO |
ceric oxide results in increased expression of CD63 protein |
CTD |
PMID:23726862 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLCA1 mRNA [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLCA1 mRNA; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of CLCA1 protein] |
CTD |
PMID:29792201 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clec10a |
C-type lectin domain containing 10A |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CLEC10A mRNA |
CTD |
PMID:29792201 |
|
NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
increases expression |
EXP |
ceric oxide results in increased expression of CX3CL1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cx3cr1 |
C-X3-C motif chemokine receptor 1 |
affects expression |
EXP |
ceric oxide affects the expression of CX3CR1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of CXCL10 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases expression |
EXP |
ceric oxide results in decreased expression of CXCL12 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
affects expression |
EXP |
ceric oxide affects the expression of CXCL9 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
increases expression |
EXP |
ceric oxide results in increased expression of CXCR2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cxcr3 |
C-X-C motif chemokine receptor 3 |
increases expression |
EXP |
ceric oxide results in increased expression of CXCR3 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:66,844,318...66,846,969
Ensembl chr X:66,844,318...66,846,969
|
|
G |
Cxcr5 |
C-X-C motif chemokine receptor 5 |
decreases expression |
EXP |
ceric oxide results in decreased expression of CXCR5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:44,842,098...44,858,425
Ensembl chr 8:44,843,413...44,857,893
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects expression |
EXP |
ceric oxide affects the expression of CYP1B1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Dbnl |
drebrin-like |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of DBNL mRNA |
CTD |
PMID:24821434 |
|
NCBI chr14:80,666,115...80,681,155
Ensembl chr14:80,666,124...80,681,155
|
|
G |
Epx |
eosinophil peroxidase |
decreases expression |
EXP |
ceric oxide results in decreased expression of EPX mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Exo1 |
exonuclease 1 |
affects expression |
EXP |
ceric oxide affects the expression of EXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression |
EXP |
ceric oxide results in increased expression of FABP4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases expression |
EXP |
ceric oxide results in decreased expression of GCLC mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
EXP |
ceric oxide results in decreased expression of GCLM mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
EXP |
ceric oxide results in decreased expression of GPX2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
EXP |
ceric oxide results in decreased expression of HBA1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:15,323,830...15,324,677
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hfe |
homeostatic iron regulator |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of HFE mRNA |
CTD |
PMID:24821434 |
|
NCBI chr17:41,413,451...41,421,502
Ensembl chr17:41,413,451...41,421,502
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression increases expression decreases expression multiple interactions |
ISO |
ceric oxide analog affects the expression of HMOX1 mRNA ceric oxide results in increased expression of HMOX1 protein ceric oxide results in decreased expression of HMOX1 mRNA ceric oxide inhibits the reaction [potassium bromate results in increased expression of HMOX1 mRNA] |
CTD |
PMID:19429248 PMID:22960666 PMID:25618551 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of ID2 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IL13 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
EXP |
ceric oxide results in increased expression of IL1A mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
EXP |
ceric oxide results in increased expression of IL1B mRNA; ceric oxide results in increased expression of IL1B protein |
CTD |
PMID:21624445 PMID:29463257 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rn |
interleukin 1 receptor antagonist |
increases expression |
EXP |
ceric oxide results in increased expression of IL1RN mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445
|
|
G |
Il2rb |
interleukin 2 receptor subunit beta |
decreases expression |
EXP |
ceric oxide results in decreased expression of IL2RB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:110,033,341...110,048,054
Ensembl chr 7:110,033,341...110,048,054
|
|
G |
Il2rg |
interleukin 2 receptor subunit gamma |
increases expression |
EXP |
ceric oxide results in increased expression of IL2RG mRNA |
CTD |
PMID:29463257 |
|
NCBI chr X:66,395,330...66,399,026
Ensembl chr X:66,392,542...66,399,823
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of IL4 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
EXP ISO |
ceric oxide results in increased expression of IL6 protein [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of IL6 mRNA |
CTD |
PMID:21624445 PMID:29792201 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf7 |
interferon regulatory factor 7 |
multiple interactions |
ISO |
ceric oxide inhibits the reaction [Antigens, Dermatophagoides results in increased expression of IRF7 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Kif13b |
kinesin family member 13B |
increases expression |
ISO |
ceric oxide analog results in increased expression of KIF13B mRNA |
CTD |
PMID:24821434 |
|
NCBI chr15:38,908,257...39,066,021
Ensembl chr15:38,924,624...39,084,879
|
|
G |
Kitlg |
KIT ligand |
increases expression |
ISO |
ceric oxide analog results in increased expression of KITLG mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Lig4 |
DNA ligase 4 |
affects expression |
EXP |
ceric oxide affects the expression of LIG4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040
|
|
G |
Lpo |
lactoperoxidase |
increases expression |
EXP |
ceric oxide results in increased expression of LPO mRNA; ceric oxide results in increased expression of LPO protein |
CTD |
PMID:29463257 |
|
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
ceric oxide results in increased phosphorylation of MAPK1 protein Acetylcysteine inhibits the reaction [ceric oxide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23416263 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Acetylcysteine inhibits the reaction [ceric oxide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23416263 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
multiple interactions increases expression |
ISO EXP |
ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of MMP12 mRNA] ceric oxide results in increased expression of MMP12 mRNA; ceric oxide results in increased expression of MMP12 protein |
CTD |
PMID:29463257 PMID:29792201 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity increases secretion |
ISO |
ceric oxide results in increased activity of MMP9 protein ceric oxide results in increased secretion of MMP9 protein |
CTD |
PMID:23726862 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
increases secretion increases expression |
ISO EXP |
ceric oxide results in increased secretion of MPO protein ceric oxide results in increased expression of MPO mRNA |
CTD |
PMID:23726862 PMID:29463257 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Msh5 |
mutS homolog 5 |
increases expression |
EXP |
ceric oxide results in increased expression of MSH5 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr20:3,773,867...3,793,337
Ensembl chr20:3,776,942...3,793,336
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of MUC1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of MUC5AC mRNA |
CTD |
PMID:29792201 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Mutyh |
mutY DNA glycosylase |
decreases expression |
EXP |
ceric oxide results in decreased expression of MUTYH mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
increases expression decreases expression |
EXP |
ceric oxide results in increased expression of NCF2 mRNA ceric oxide results in decreased expression of NCF2 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
ceric oxide affects the localization of NFE2L2 protein |
CTD |
PMID:19429248 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngb |
neuroglobin |
decreases expression |
EXP |
ceric oxide results in decreased expression of NGB mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 6:106,744,378...106,749,830
Ensembl chr 6:106,744,378...106,749,830
|
|
G |
Noxo1 |
NADPH oxidase organizer 1 |
increases expression |
EXP |
ceric oxide results in increased expression of NOXO1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr10:13,723,253...13,726,008
Ensembl chr10:13,721,473...13,726,061
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of NQO1 mRNA |
CTD |
PMID:29792201 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Opcml |
opioid binding protein/cell adhesion molecule-like |
increases expression |
EXP |
ceric oxide results in increased expression of OPCML mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 8:26,788,988...27,304,551
Ensembl chr 8:26,192,841...27,300,620
|
|
G |
Osm |
oncostatin M |
affects expression |
EXP |
ceric oxide affects the expression of OSM mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Pf4 |
platelet factor 4 |
increases expression |
EXP |
ceric oxide results in increased expression of PF4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
RT1-CE16 |
RT1 class I, locus CE16 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of HLA-A mRNA |
CTD |
PMID:24821434 |
|
NCBI chr20:3,257,109...3,260,747
Ensembl chr20:3,257,123...3,279,563
|
|
G |
Scd |
stearoyl-CoA desaturase |
affects expression |
EXP |
ceric oxide affects the expression of SCD1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Sectm1b |
secreted and transmembrane 1B |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of SECTM1 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr10:106,324,070...106,333,779
Ensembl chr10:106,325,203...106,333,769
|
|
G |
Slc26a4 |
solute carrier family 26 member 4 |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of SLC26A4 mRNA [Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of SLC26A4 mRNA; ceric oxide promotes the reaction [Antigens, Dermatophagoides results in increased expression of SLC26A4 mRNA] |
CTD |
PMID:29792201 |
|
NCBI chr 6:48,107,575...48,153,762
Ensembl chr 6:48,107,588...48,145,703
|
|
G |
Smug1 |
single-strand-selective monofunctional uracil-DNA glycosylase 1 |
increases expression |
EXP |
ceric oxide results in increased expression of SMUG1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 7:134,288,565...134,302,179
Ensembl chr 7:134,287,675...134,297,226
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
ceric oxide inhibits the reaction [potassium bromate results in increased expression of SOD2 mRNA] ceric oxide results in increased expression of SOD2 mRNA |
CTD |
PMID:25618551 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
ceric oxide results in decreased expression of SPP1 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tafazzin |
tafazzin, phospholipid-lysophospholipid transacylase |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TAFAZZIN mRNA |
CTD |
PMID:24821434 |
|
NCBI chr X:152,065,539...152,076,178
Ensembl chr X:152,065,609...152,074,001
|
|
G |
Tirap |
TIR domain containing adaptor protein |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TIRAP mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 8:33,531,724...33,548,508
Ensembl chr 8:33,531,725...33,547,432
|
|
G |
Tlr6 |
toll-like receptor 6 |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TLR6 mRNA |
CTD |
PMID:24821434 |
|
NCBI chr14:43,362,164...43,374,500
Ensembl chr14:43,362,164...43,375,685
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
EXP ISO |
ceric oxide results in increased expression of TNF protein |
CTD |
PMID:21624445 PMID:27693598 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf4 |
TNF superfamily member 4 |
affects expression |
EXP |
ceric oxide affects the expression of TNFSF4 mRNA |
CTD |
PMID:29463257 |
|
NCBI chr13:73,723,329...73,746,809
Ensembl chr13:73,723,329...73,746,788
|
|
G |
Tollip |
toll interacting protein |
decreases expression |
ISO |
ceric oxide analog results in decreased expression of TOLLIP mRNA |
CTD |
PMID:24821434 |
|
NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625
|
|
G |
Tp53 |
tumor protein p53 |
increases phosphorylation |
ISO |
ceric oxide results in increased phosphorylation of TP53 protein |
CTD |
PMID:24987704 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tslp |
thymic stromal lymphopoietin |
multiple interactions |
ISO |
[Antigens, Dermatophagoides co-treated with ceric oxide] results in increased expression of TSLP mRNA |
CTD |
PMID:29792201 |
|
NCBI chr18:24,447,409...24,454,244
Ensembl chr18:24,449,844...24,453,548
|
|
G |
Txnip |
thioredoxin interacting protein |
decreases expression |
EXP |
ceric oxide results in decreased expression of TXNIP mRNA |
CTD |
PMID:29463257 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
affects expression |
ISO |
Cerium affects the expression of AHR mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Atf4 |
activating transcription factor 4 |
affects expression |
ISO |
Cerium affects the expression of ATF4 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Cerium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Cerium results in decreased expression of HIF1A mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Mtf1 |
metal-regulatory transcription factor 1 |
decreases expression |
ISO |
Cerium results in decreased expression of MTF1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 5:137,062,319...137,107,136
Ensembl chr 5:137,062,376...137,107,136
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
ISO |
Cerium results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression |
ISO |
Cerium results in decreased expression of NFKB1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
Cerium results in decreased expression of PPARG mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
affects expression |
ISO |
Cerium affects the expression of STAT1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat2 |
signal transducer and activator of transcription 2 |
affects expression |
ISO |
Cerium affects the expression of STAT2 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr 7:702,565...718,349
Ensembl chr 7:702,495...718,967
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO |
Cerium results in decreased expression of TP53 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Xbp1 |
X-box binding protein 1 |
decreases expression |
ISO |
Cerium results in decreased expression of XBP1 mRNA |
CTD |
PMID:35641671 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Alb |
albumin |
affects expression |
ISO |
cerous chloride affects the expression of ALB mRNA |
CTD |
PMID:23139204 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of ALOX12 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of ALOX12 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of AOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Apoa4 |
apolipoprotein A4 |
affects expression |
ISO |
cerous chloride affects the expression of APOA4 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoe |
apolipoprotein E |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of APOE mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of APOE mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
cerous chloride results in increased expression of B2M mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of CAT mRNA cerous chloride results in decreased expression of CAT mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of CCL5 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of CCL5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] affects the expression of CCS mRNA cerous chloride results in decreased expression of CCS mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO |
cerous chloride results in decreased expression of CDKN1A mRNA |
CTD |
PMID:23139204 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cel |
carboxyl ester lipase |
increases expression |
ISO |
cerous chloride results in increased expression of CEL mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035
|
|
G |
Cfd |
complement factor D |
affects expression |
ISO |
cerous chloride affects the expression of CFD mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases expression |
ISO |
cerous chloride results in increased expression of CHUK mRNA; cerous chloride results in increased expression of CHUK protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cygb |
cytoglobin |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of CYGB mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of CYGB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CYP1A1 |
CTD |
PMID:23712967 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
affects expression |
ISO |
cerous chloride affects the expression of CYP51 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression |
ISO |
cerous chloride results in increased expression of CYP7B1 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
affects expression |
ISO |
cerous chloride affects the expression of CYP8B1 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
cerous chloride results in decreased expression of DHCR24 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects expression |
ISO |
cerous chloride affects the expression of DHCR7 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Duox1 |
dual oxidase 1 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of DUOX1 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563
|
|
G |
Duox2 |
dual oxidase 2 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUSP1 mRNA cerous chloride affects the expression of DUSP1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
affects expression |
ISO |
cerous chloride affects the expression of EBP mRNA |
CTD |
PMID:23139204 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
affects expression |
ISO |
cerous chloride affects the expression of EHHADH mRNA |
CTD |
PMID:23139204 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of EPHX2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of EPHX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Epx |
eosinophil peroxidase |
decreases expression |
ISO |
cerous chloride results in decreased expression of EPX mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of FOXM1 mRNA cerous chloride results in decreased expression of FOXM1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Fth1 |
ferritin heavy chain 1 |
increases expression |
ISO |
cerous chloride results in increased expression of FTH1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of GAPDH mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of GAPDH mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of GCLC mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of GCLC mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases expression |
ISO |
cerous chloride results in decreased expression of GCLM mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
affects expression |
ISO |
cerous chloride affects the expression of GPD2 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of GPX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of GPX3 mRNA cerous chloride affects the expression of GPX3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
affects expression |
ISO |
cerous chloride affects the expression of GPX4 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of GPX7 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of GPX7 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
affects expression |
ISO |
cerous chloride affects the expression of GRB2 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
cerous chloride results in decreased expression of GSTP1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of GSTZ1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Gtf2i |
general transcription factor II I |
decreases expression |
ISO |
cerous chloride results in decreased expression of GTF2I mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:22,400,933...22,476,243
Ensembl chr12:22,401,431...22,476,243
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of HMOX1 mRNA cerous chloride affects the expression of HMOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
decreases expression |
ISO |
cerous chloride results in decreased expression of HSPA1A mRNA |
CTD |
PMID:28954213 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
cerous chloride results in increased expression of IFNG |
CTD |
PMID:23712967 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases expression |
ISO |
cerous chloride results in increased expression of IKBKB mRNA; cerous chloride results in increased expression of IKBKB protein |
CTD |
PMID:21656643 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
increases expression |
ISO |
cerous chloride results in increased expression of IL10 |
CTD |
PMID:23712967 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il18 |
interleukin 18 |
increases expression |
ISO |
cerous chloride results in increased expression of IL18 |
CTD |
PMID:23712967 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
cerous chloride results in increased expression of IL1B |
CTD |
PMID:23712967 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression increases expression |
ISO |
cerous chloride results in decreased expression of IL2 mRNA; cerous chloride results in decreased expression of IL2 protein cerous chloride results in increased expression of IL2 |
CTD |
PMID:21656643 PMID:23712967 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
increases expression |
ISO |
cerous chloride results in increased expression of IL4 |
CTD |
PMID:23712967 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
IL6 mutant form inhibits the reaction [cerous chloride results in increased expression of SAA protein] cerous chloride results in increased expression of IL6; cerous chloride results in increased expression of IL6 protein |
CTD |
PMID:16204935 PMID:23712967 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
affects expression |
ISO |
cerous chloride affects the expression of JUN mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lpo |
lactoperoxidase |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of LPO mRNA cerous chloride results in increased expression of LPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
cerous chloride results in increased expression of MAP1LC3B protein |
CTD |
PMID:38253231 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map4k4 |
mitogen-activated protein kinase kinase kinase kinase 4 |
increases expression |
ISO |
cerous chloride results in increased expression of MAP4K4 mRNA; cerous chloride results in increased expression of MAP4K4 protein |
CTD |
PMID:21656643 |
|
NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
|
|
G |
Mb |
myoglobin |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of MB mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of MB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbl2 |
mannose binding lectin 2 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of MBL2 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of MBL2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:228,016,439...228,024,736
|
|
G |
Mif |
macrophage migration inhibitory factor |
increases expression |
ISO |
cerous chloride results in increased expression of MIF |
CTD |
PMID:23712967 |
|
NCBI chr20:12,790,919...12,791,784
Ensembl chr20:12,790,902...12,799,504
|
|
G |
Mpo |
myeloperoxidase |
affects expression |
ISO |
cerous chloride affects the expression of MPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpv17 |
mitochondrial inner membrane protein MPV17 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of MPV17 mRNA cerous chloride results in decreased expression of MPV17 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:25,221,668...25,236,241
Ensembl chr 6:25,222,896...25,236,244
|
|
G |
Msra |
methionine sulfoxide reductase A |
decreases expression |
ISO |
cerous chloride results in decreased expression of MSRA mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:38,363,459...38,677,406
Ensembl chr15:38,351,445...38,676,585
|
|
G |
Mt1 |
metallothionein 1 |
increases expression multiple interactions |
ISO |
cerous chloride results in increased expression of MT1 protein cerous chloride promotes the reaction [Zinc binds to MT1 protein] |
CTD |
PMID:15964310 PMID:16204935 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
ISO |
cerous chloride promotes the reaction [Zinc binds to MT2 protein] cerous chloride results in increased expression of MT2 protein |
CTD |
PMID:15964310 PMID:16204935 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of NCF2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases expression |
ISO |
cerous chloride results in increased expression of NFKB1 mRNA; cerous chloride results in increased expression of NFKB1 protein |
CTD |
PMID:21656643 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkb2 |
nuclear factor kappa B subunit 2 |
increases expression |
ISO |
cerous chloride results in increased expression of NFKB2 mRNA; cerous chloride results in increased expression of NFKB2 protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
|
|
G |
Nfkbib |
NFKB inhibitor beta |
decreases expression |
ISO |
cerous chloride results in decreased expression of NFKBIB mRNA; cerous chloride results in decreased expression of NFKBIB protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
|
|
G |
Nnmt |
nicotinamide N-methyltransferase |
affects expression |
ISO |
cerous chloride affects the expression of NNMT mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:48,928,663...48,947,734
Ensembl chr 8:48,933,598...48,946,655
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of NOS2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of NOS2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions |
ISO |
cerous chloride results in decreased expression of and affects the localization of NPM1 protein |
CTD |
PMID:38253231 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases expression |
ISO |
cerous chloride results in decreased expression of NT5E mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nudt1 |
nudix hydrolase 1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of NUDT1 mRNA cerous chloride results in decreased expression of NUDT1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:14,302,514...14,309,559
Ensembl chr12:14,302,694...14,305,826
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression multiple interactions |
ISO |
cerous chloride affects the expression of PCNA protein [cerous chloride co-treated with lanthanum chloride] affects the expression of PCNA protein |
CTD |
PMID:28954213 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pnkp |
polynucleotide kinase 3'-phosphatase |
decreases expression |
ISO |
cerous chloride results in decreased expression of PNKP mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:95,341,465...95,346,921
Ensembl chr 1:95,341,620...95,346,920
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PRDX1 mRNA cerous chloride results in decreased expression of PRDX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx2 |
peroxiredoxin 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PRDX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of PRDX5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PREX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of PTGS2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pxdn |
peroxidasin |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PXDN mRNA cerous chloride results in decreased expression of PXDN mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[cerous chloride co-treated with Cisplatin] results in increased expression of RAD51 protein |
CTD |
PMID:38253231 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
ISO |
cerous chloride results in increased expression of RELA mRNA; cerous chloride results in increased expression of RELA protein |
CTD |
PMID:21656643 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Scara3 |
scavenger receptor class A, member 3 |
decreases expression |
ISO |
cerous chloride results in decreased expression of SCARA3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:40,139,873...40,172,866
Ensembl chr15:40,140,161...40,172,894
|
|
G |
Selenop |
selenoprotein P |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SELENOP mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions decreases expression increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SIRT2 mRNA cerous chloride results in decreased expression of SIRT2 mRNA cerous chloride results in increased expression of SIRT2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity |
ISO |
cerous chloride results in decreased activity of SOD1 protein |
CTD |
PMID:15964310 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases activity multiple interactions |
ISO |
cerous chloride results in decreased activity of SOD2 protein [cerous chloride co-treated with lanthanum chloride] results in increased expression of SOD2 mRNA |
CTD |
PMID:15964310 PMID:28954213 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SQSTM1 mRNA cerous chloride affects the expression of SQSTM1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srxn1 |
sulfiredoxin 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SRXN1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stk25 |
serine/threonine kinase 25 |
decreases expression multiple interactions |
ISO |
cerous chloride results in decreased expression of STK25 mRNA [cerous chloride co-treated with lanthanum chloride] results in decreased expression of STK25 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:94,161,834...94,174,095
Ensembl chr 9:94,161,836...94,174,244
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TGFB1 |
CTD |
PMID:23712967 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr2 |
toll-like receptor 2 |
increases expression |
ISO |
cerous chloride results in increased expression of TLR2 mRNA; cerous chloride results in increased expression of TLR2 protein |
CTD |
PMID:21656643 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression |
ISO |
cerous chloride results in increased expression of TLR4 mRNA; cerous chloride results in increased expression of TLR4 protein |
CTD |
PMID:21656643 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
increases expression |
ISO |
cerous chloride results in increased expression of TNF; cerous chloride results in increased expression of TNF mRNA; cerous chloride results in increased expression of TNF protein |
CTD |
PMID:21656643 PMID:23712967 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TXN mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
cerous chloride results in increased expression of TXNRD1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Txnrd2 |
thioredoxin reductase 2 |
decreases expression |
ISO |
cerous chloride results in decreased expression of TXNRD2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] affects the expression of UCP2 mRNA cerous chloride results in decreased expression of UCP2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Zap70 |
zeta chain of T cell receptor associated protein kinase 70 |
affects expression |
ISO |
cerous chloride affects the expression of ZAP70 mRNA |
CTD |
PMID:23139204 |
|
NCBI chr 9:38,989,750...39,011,701
Ensembl chr 9:38,989,750...39,011,700
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Erbium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
gadobutrol results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:37437671 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
gadobutrol results in decreased expression of FABP4 mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
gadobutrol results in decreased expression of PPARG mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
gadodiamide results in decreased expression of ADIPOQ mRNA; gadodiamide results in decreased expression of ADIPOQ protein |
CTD |
PMID:37437671 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
gadodiamide results in increased phosphorylation of AKT1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases expression |
ISO |
gadodiamide results in increased expression of ALDH1A1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ankrd22 |
ankyrin repeat domain 22 |
increases expression |
ISO |
gadodiamide results in increased expression of ANKRD22 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:231,639,035...231,670,537
Ensembl chr 1:231,639,314...231,670,381
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
gadodiamide results in increased expression of ATM mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases expression |
ISO |
gadodiamide results in increased expression of ATP8B1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression increases secretion |
ISO EXP |
gadodiamide results in increased expression of CCL2 mRNA gadodiamide results in increased expression of CCL2 mRNA; gadodiamide results in increased expression of CCL2 protein gadodiamide results in increased secretion of CCL2 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
EXP |
gadodiamide results in increased expression of CCL4 protein |
CTD |
PMID:20938346 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
EXP |
gadodiamide results in increased expression of CCL7 protein |
CTD |
PMID:20938346 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Cep15 |
centrosomal protein 15 |
increases expression |
ISO |
gadodiamide results in increased expression of CEP15 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr15:12,815,159...12,835,115
Ensembl chr15:12,818,385...12,833,838
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression increases secretion |
ISO EXP |
gadodiamide results in increased expression of CXCL10 mRNA gadodiamide results in increased expression of CXCL10 protein gadodiamide results in increased secretion of CXCL10 protein |
CTD |
PMID:20938346 PMID:20959327 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases secretion increases expression |
ISO |
gadodiamide results in increased secretion of CXCL11 protein gadodiamide results in increased expression of CXCL11 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL12 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
gadodiamide results in increased expression of CXCL9 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
gadodiamide results in decreased expression of FABP4 mRNA; gadodiamide results in decreased expression of FABP4 protein |
CTD |
PMID:37437671 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IDO1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Ifi44l |
interferon-induced protein 44-like |
increases expression |
ISO |
gadodiamide results in increased expression of IFI44L mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
gadodiamide results in increased expression of IFIT3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifng |
interferon gamma |
increases expression |
ISO |
gadodiamide results in increased expression of IFNG mRNA; gadodiamide results in increased expression of IFNG protein |
CTD |
PMID:19404939 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadodiamide results in increased expression of IL13 mRNA; gadodiamide results in increased expression of IL13 protein |
CTD |
PMID:19404939 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression |
EXP |
gadodiamide results in increased expression of IL1A protein |
CTD |
PMID:20938346 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il4 |
interleukin 4 |
increases expression affects expression |
ISO |
gadodiamide results in increased expression of IL4 protein gadodiamide affects the expression of IL4 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il4i1 |
interleukin 4 induced 1 |
increases expression |
ISO |
gadodiamide results in increased expression of IL4I1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:95,299,457...95,324,564
Ensembl chr 1:95,295,601...95,324,562
|
|
G |
Il6 |
interleukin 6 |
affects expression increases expression |
ISO |
gadodiamide affects the expression of IL6 protein gadodiamide results in increased expression of IL6 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kitlg |
KIT ligand |
increases expression |
EXP |
gadodiamide results in increased expression of KITLG protein |
CTD |
PMID:20938346 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19561517 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [gadodiamide results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19561517 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions increases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased expression of MMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of MMP1 protein] gadodiamide results in increased expression of MMP1 mRNA; gadodiamide results in increased expression of MMP1 protein |
CTD |
PMID:19561517 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
ISO |
gadodiamide results in increased expression of NOS2 protein |
CTD |
PMID:20959327 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nxpe3 |
neurexophilin and PC-esterase domain family, member 3 |
increases expression |
ISO |
gadodiamide results in increased expression of NXPE3 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
gadodiamide results in decreased expression of PPARG mRNA; gadodiamide results in decreased expression of PPARG protein |
CTD |
PMID:37437671 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases localization |
ISO |
gadodiamide results in increased localization of RELA protein |
CTD |
PMID:20959327 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoq |
ras homolog family member Q |
increases expression |
ISO |
gadodiamide results in increased expression of RHOQ mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 6:7,613,632...7,652,047
|
|
G |
Rit1 |
Ras-like without CAAX 1 |
increases expression |
ISO |
gadodiamide results in increased expression of RIT1 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 2:174,180,742...174,195,455
Ensembl chr 2:174,180,848...174,195,455
|
|
G |
Rnf125 |
ring finger protein 125 |
increases expression |
ISO |
gadodiamide results in increased expression of RNF125 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr18:12,254,066...12,275,719
Ensembl chr18:12,253,852...12,275,983
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
increases expression |
ISO |
gadodiamide results in increased expression of RSAD2 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
increases expression |
ISO |
gadodiamide results in increased expression of SLC39A10 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:54,876,141...54,960,325
|
|
G |
Spn |
sialophorin |
increases expression |
ISO |
gadodiamide results in increased expression of SPN mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 1:181,746,937...181,759,564
Ensembl chr 1:181,746,429...181,759,628
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
increases expression |
EXP |
gadodiamide results in increased expression of SPP1 protein |
CTD |
PMID:20938346 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO EXP |
gadodiamide results in increased expression of TGFB1 mRNA; gadodiamide results in increased expression of TGFB1 protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO EXP |
gadodiamide results in increased expression of TIMP1 mRNA; gadodiamide results in increased expression of TIMP1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [gadodiamide results in increased expression of TIMP1 protein]; U 0126 inhibits the reaction [gadodiamide results in increased expression of TIMP1 protein] |
CTD |
PMID:19561517 PMID:20938346 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Ubd |
ubiquitin D |
increases expression |
ISO |
gadodiamide results in increased expression of UBD mRNA |
CTD |
PMID:20959327 |
|
NCBI chr20:1,385,487...1,387,438
Ensembl chr20:1,385,864...1,408,639 Ensembl chr20:1,385,864...1,408,639
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO EXP |
gadodiamide results in increased expression of VEGFA mRNA; gadodiamide results in increased expression of VEGFA protein |
CTD |
PMID:19404939 PMID:20938346 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Wdr5 |
WD repeat domain 5 |
increases expression |
ISO |
gadodiamide results in increased expression of WDR5 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr 3:10,836,964...10,856,682
Ensembl chr 3:10,837,025...10,856,671
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
increases expression |
ISO |
gadodiamide results in increased expression of XIAP mRNA |
CTD |
PMID:20959327 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zfp652 |
zinc finger protein 652 |
increases expression |
ISO |
gadodiamide results in increased expression of ZNF652 mRNA |
CTD |
PMID:20959327 |
|
NCBI chr10:80,626,555...80,706,397
Ensembl chr10:80,649,400...80,698,674
|
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of ACACA mRNA |
CTD |
PMID:34878122 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in decreased expression of BCL2 protein |
CTD |
PMID:34878122 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of BMAL1 protein |
CTD |
PMID:34878122 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
EXP ISO |
Gadolinium results in increased activity of CASP3 protein [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CASP3 mRNA |
CTD |
PMID:20398695 PMID:34878122 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
EXP |
[Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Calcium; [Gadolinium binds to and results in increased activity of CASR protein] which results in increased abundance of Inositol Phosphates; Gadolinium binds to and results in increased activity of CASR protein; Gadolinium inhibits the reaction [Calcium binds to and results in increased activity of CASR protein] |
CTD |
PMID:10231437 PMID:11071898 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]] |
CTD |
PMID:21127073 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CPT1A mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [Glucose results in increased expression of DDIT3 protein] |
CTD |
PMID:30076216 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9109525 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] |
CTD |
PMID:9109525 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Gnaq |
G protein subunit alpha q |
increases response to substance |
ISO |
GNAQ protein results in increased susceptibility to Gadolinium |
CTD |
PMID:15068510 |
|
NCBI chr 1:213,425,631...213,671,947
Ensembl chr 1:213,424,465...213,667,672
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of HIF1A mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [Glucose results in increased expression of HSPA5 protein] |
CTD |
PMID:30076216 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Ift88 |
intraflagellar transport 88 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [IFT88 protein mutant form results in increased uptake of Calcium] |
CTD |
PMID:16396941 |
|
NCBI chr15:31,573,325...31,666,068
Ensembl chr15:31,573,376...31,672,147
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL1B mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL6 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Gadolinium inhibits the reaction [Calcimycin results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11914123 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Gadolinium inhibits the reaction [Calcimycin results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11914123 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFE2L2 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFKB1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of RELA protein |
CTD |
PMID:34878122 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
affects response to substance |
ISO |
S100A6 protein affects the susceptibility to Gadolinium |
CTD |
PMID:15068510 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SPP1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SQSTM1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of TGFB1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [allyl isothiocyanate results in increased activity of TRPA1 protein] |
CTD |
PMID:15843607 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions |
ISO |
Gadolinium affects the localization of and results in decreased activity of TRPC3 protein |
CTD |
PMID:16522635 |
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
multiple interactions |
ISO |
2-aminoethoxydiphenyl borate promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Calcium promotes the reaction [resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]]; CAT protein inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]; Gallic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]; resveratrol promotes the reaction [Ascorbic Acid inhibits the reaction [Gadolinium promotes the reaction [TRPC5 protein results in increased transport of Calcium]]] |
CTD |
PMID:21127073 |
|
NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
decreases activity |
ISO |
Gadolinium results in decreased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Gadolinium inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
multiple interactions decreases activity |
EXP |
[Gadolinium results in decreased activity of TRPV4 protein] which results in decreased susceptibility to Buthionine Sulfoximine |
CTD |
PMID:20064552 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
multiple interactions increases uptake |
ISO |
Gadolinium inhibits the reaction [TRPV6 protein results in increased uptake of Calcium] TRPV6 protein results in increased uptake of Gadolinium |
CTD |
PMID:21146870 |
|
NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of ABCC4 mRNA] |
CTD |
PMID:18757529 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
gadolinium chloride promotes the reaction [Ethanol results in decreased expression of ACACA protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of ACACA mRNA |
CTD |
PMID:28882574 PMID:34878122 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acot1 |
acyl-CoA thioesterase 1 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of ACOT1 mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr 6:103,636,173...103,644,167
Ensembl chr 6:103,636,041...103,644,163
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:11408273 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgre1 |
adhesion G protein-coupled receptor E1 |
multiple interactions |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of ADGRE1 mRNA gadolinium chloride inhibits the reaction [Ethanol results in increased expression of ADGRE1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:37437671 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of APOB mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Atf4 |
activating transcription factor 4 |
affects expression |
EXP |
gadolinium chloride affects the expression of ATF4 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions increases expression affects expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ATF6 protein] gadolinium chloride affects the expression of ATF6 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in decreased expression of BCL2 protein |
CTD |
PMID:34878122 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of BMAL1 protein |
CTD |
PMID:34878122 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [Carbon Tetrachloride results in increased expression of BMP2 mRNA] |
CTD |
PMID:17158861 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CASP3 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Triiodothyronine co-treated with Hexachlorocyclohexane] results in decreased activity of CAT protein] |
CTD |
PMID:12516873 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CCL2 mRNA]; gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of CCL2 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
gadolinium chloride results in increased expression of CCNE1 |
CTD |
PMID:19184457 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cd163 |
CD163 molecule |
multiple interactions |
EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD163 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD163 mRNA] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO EXP |
gadolinium chloride inhibits the reaction [[Dietary Fats co-treated with bromodichloromethane] results in increased expression of CD68 mRNA] [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 mRNA; [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of CD68 protein; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CD68 mRNA] |
CTD |
PMID:23438451 PMID:25813056 PMID:26177832 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP ISO |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of CPT1A mRNA] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of CPT1A mRNA |
CTD |
PMID:22648072 PMID:34878122 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL1 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of CXCL2 mRNA] gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of CXCL2 mRNA] |
CTD |
PMID:22157104 PMID:26177832 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Progesterone promotes the reaction [Halothane results in increased expression of CXCL1 mRNA]]; gadolinium chloride inhibits the reaction [Progesterone results in increased expression of CXCL1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP1A2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Phenobarbital results in increased expression of CYP2B1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B1 protein] |
CTD |
PMID:10918498 PMID:18202523 |
|
NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2B2 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP2C11 protein] |
CTD |
PMID:18079364 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP2E1 protein] |
CTD |
PMID:18202523 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP3A2 mRNA]; gadolinium chloride inhibits the reaction [Styrene results in increased expression of CYP3A2 protein]; gadolinium chloride inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased activity of and results in decreased expression of CYP3A2 protein] |
CTD |
PMID:18079364 PMID:18202523 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of CYP4A1 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression affects expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of DDIT3 protein] gadolinium chloride affects the expression of DDIT3 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases expression |
EXP |
gadolinium chloride results in increased expression of EIF2AK3 protein |
CTD |
PMID:21198628 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions increases expression |
EXP |
Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of ERN1 protein] |
CTD |
PMID:21198628 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of FABP4 mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of FASN mRNA gadolinium chloride promotes the reaction [Ethanol results in decreased expression of FASN protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of GPT protein]; gadolinium chloride inhibits the reaction [Vitamin A results in increased activity of GPT protein] gadolinium chloride inhibits the reaction [Amiodarone promotes the reaction [Dexamethasone results in increased expression of GPT protein]] |
CTD |
PMID:8627517 PMID:25900201 PMID:26177832 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hamp |
hepcidin antimicrobial peptide |
increases expression |
EXP |
gadolinium chloride results in increased expression of HAMP |
CTD |
PMID:19721414 |
|
NCBI chr 1:86,170,926...86,172,865
Ensembl chr 1:86,170,901...86,172,891
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of HIF1A mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hjv |
hemojuvelin BMP co-receptor |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of HJV |
CTD |
PMID:19721414 |
|
NCBI chr 2:184,065,944...184,069,851
Ensembl chr 2:184,065,970...184,069,850
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased secretion of HMGB1 protein] |
CTD |
PMID:26177832 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of HMGCS2 mRNA] |
CTD |
PMID:25813056 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of HSPA1A protein] |
CTD |
PMID:12963478 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression multiple interactions affects expression |
EXP |
gadolinium chloride results in increased expression of HSPA5 protein Acetylcysteine inhibits the reaction [gadolinium chloride results in increased expression of HSPA5 protein] gadolinium chloride affects the expression of HSPA5 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [[Progesterone co-treated with Halothane] results in increased expression of ICAM1 mRNA] |
CTD |
PMID:22157104 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
affects expression increases expression |
ISO |
gadolinium chloride affects the expression of IFNG protein gadolinium chloride results in increased expression of IFNG mRNA |
CTD |
PMID:15590129 PMID:19404939 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGF1 protein] |
CTD |
PMID:16522730 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp3 |
insulin-like growth factor binding protein 3 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Lipopolysaccharides results in decreased expression of IGFBP3 protein] |
CTD |
PMID:16522730 |
|
NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL10 mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in decreased expression of IL10 protein] |
CTD |
PMID:22648072 PMID:26177832 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
increases expression |
ISO |
gadolinium chloride results in increased expression of IL13 mRNA |
CTD |
PMID:19404939 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of IL1A protein] |
CTD |
PMID:15025948 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
gadolinium chloride results in increased expression of IL1B [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL1B mRNA [gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL1B mRNA; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of IL1B protein] |
CTD |
PMID:19721414 PMID:22648072 PMID:25813056 PMID:34878122 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
affects expression |
ISO |
gadolinium chloride affects the expression of IL4 mRNA; gadolinium chloride affects the expression of IL4 protein |
CTD |
PMID:19404939 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of IL6 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of IL6 protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of IL6 mRNA gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] gadolinium chloride results in increased expression of IL6 gadolinium chloride results in increased expression of IL6 mRNA |
CTD |
PMID:12127824 PMID:12963478 PMID:19404939 PMID:19721414 PMID:24849676 PMID:25813056 PMID:26177832 PMID:34878122 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lipe |
lipase E, hormone sensitive type |
multiple interactions |
ISO |
gadolinium chloride inhibits the reaction [Ethanol results in increased phosphorylation of LIPE protein] |
CTD |
PMID:28882574 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Ltb |
lymphotoxin beta |
increases expression |
ISO |
gadolinium chloride results in increased expression of LTB mRNA |
CTD |
PMID:15590129 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation multiple interactions increases activity |
ISO EXP |
gadolinium chloride results in decreased phosphorylation of MAPK1 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK1 protein] gadolinium chloride results in increased activity of MAPK1 protein Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions increases activity |
ISO EXP |
gadolinium chloride results in decreased phosphorylation of MAPK3 protein gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased phosphorylation of MAPK3 protein] Pertussis Toxin inhibits the reaction [gadolinium chloride results in decreased phosphorylation of MAPK3 protein] gadolinium chloride results in increased activity of MAPK3 protein |
CTD |
PMID:12493575 PMID:21605080 PMID:26177832 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions increases expression |
EXP |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP13 mRNA; SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP13 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
multiple interactions increases expression |
EXP |
[Dimethylnitrosamine co-treated with gadolinium chloride] results in increased expression of MMP14 mRNA gadolinium chloride results in increased expression of MMP14 mRNA; gadolinium chloride results in increased expression of MMP14 protein |
CTD |
PMID:12493575 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions |
EXP |
gadolinium chloride results in increased expression of MMP9 mRNA SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP9 mRNA] |
CTD |
PMID:12493575 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Thioacetamide results in increased activity of MPO protein] |
CTD |
PMID:12963478 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFE2L2 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of NFKB1 protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of NFKB1 mRNA |
CTD |
PMID:15025948 PMID:34878122 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression |
EXP |
gadolinium chloride results in increased expression of NOS2 mRNA |
CTD |
PMID:15135310 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of PDGFA mRNA |
CTD |
PMID:14578756 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of PDGFB mRNA |
CTD |
PMID:14578756 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
gadolinium chloride promotes the reaction [perfluoro-n-nonanoic acid results in increased expression of PPARA mRNA] |
CTD |
PMID:22648072 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of PPARG mRNA |
CTD |
PMID:37437671 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases activity |
ISO |
gadolinium chloride results in increased activity of PTK2 |
CTD |
PMID:19184457 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
increases phosphorylation |
ISO |
gadolinium chloride results in increased phosphorylation of RB1 protein |
CTD |
PMID:19184457 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased activity of RELA protein] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of RELA protein |
CTD |
PMID:15025948 PMID:34878122 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A8 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of S100A9 mRNA] |
CTD |
PMID:26177832 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
EXP ISO |
gadolinium chloride promotes the reaction [[Fructose co-treated with Copper deficiency] results in decreased expression of SCD1 mRNA] gadolinium chloride promotes the reaction [Ethanol results in decreased expression of SCD1 protein] |
CTD |
PMID:25813056 PMID:28882574 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
decreases expression |
EXP |
gadolinium chloride results in decreased expression of SLC40A1 |
CTD |
PMID:19721414 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SPP1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of SQSTM1 mRNA |
CTD |
PMID:34878122 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [[Fructose co-treated with Copper deficiency] results in increased expression of SREBF1 protein] |
CTD |
PMID:25813056 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression affects expression |
EXP ISO |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 mRNA]; gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA] [gadolinium chloride results in increased abundance of Gadolinium] which results in increased expression of TGFB1 mRNA gadolinium chloride results in increased expression of TGFB1 protein gadolinium chloride results in increased expression of TGFB1 mRNA gadolinium chloride affects the expression of TGFB1 mRNA |
CTD |
PMID:11408273 PMID:15590129 PMID:15964588 PMID:19404939 PMID:34878122 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TLR4 mRNA; gadolinium chloride inhibits the reaction [[Buthionine Sulfoximine results in increased susceptibility to Methimazole] which results in increased expression of TLR4 protein] |
CTD |
PMID:25813056 PMID:26177832 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression increases expression |
EXP ISO |
[gadolinium chloride co-treated with Fructose co-treated with Copper deficiency] results in decreased expression of TNF mRNA; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [Hexachlorocyclohexane results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; gadolinium chloride inhibits the reaction [perfluoro-n-nonanoic acid results in increased expression of TNF protein]; gadolinium chloride inhibits the reaction [Thioacetamide results in increased expression of TNF protein] gadolinium trichloride inhibits the reaction [estriol enhances the reaction [lipopolysaccharide increases expression of Tnf mRNA in liver]] gadolinium chloride inhibits the reaction [lead acetate promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF protein]]; gadolinium chloride inhibits the reaction [perfluorodecanoic acid results in increased expression of TNF protein] gadolinium chloride results in increased expression of TNF gadolinium chloride results in increased expression of TNF mRNA |
CTD RGD |
PMID:12127824 PMID:12963478 PMID:14687926 PMID:15025948 PMID:15590129 PMID:16581537 PMID:18757529 PMID:19721414 PMID:22648072 PMID:25813056 PMID:9575848 More...
|
RGD:15017096 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFRSF11B mRNA |
CTD |
PMID:21605080 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
gadolinium chloride results in increased expression of TNFSF10 mRNA |
CTD |
PMID:15590129 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
decreases expression |
ISO |
gadolinium chloride results in decreased expression of TNFSF11 mRNA |
CTD |
PMID:21605080 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
EXP |
gadolinium chloride inhibits the reaction [Carbon Tetrachloride results in increased expression of UCP2 mRNA] |
CTD |
PMID:18314881 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
gadolinium chloride results in increased expression of VEGFA mRNA; gadolinium chloride results in increased expression of VEGFA protein |
CTD |
PMID:19404939 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases splicing |
EXP |
gadolinium chloride results in increased splicing of XBP1 mRNA |
CTD |
PMID:21198628 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Holmium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases phosphorylation |
EXP |
Lanthanum results in decreased phosphorylation of CAMK4 protein |
CTD |
PMID:21695898 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [Calcium binds to and results in increased activity of CASR protein]; Lanthanum inhibits the reaction [CASR protein results in increased uptake of Calcium]; Lanthanum inhibits the reaction [Spermine binds to and results in increased activity of CASR protein] |
CTD |
PMID:17041782 PMID:21562303 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [[Carbachol results in increased activity of CHRM1 protein] which results in increased abundance of Calcium] |
CTD |
PMID:18316702 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases phosphorylation |
EXP |
Lanthanum results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:21695898 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Drd1 |
dopamine receptor D1 |
multiple interactions |
EXP |
Lanthanum inhibits the reaction [SCH 23390 binds to DRD1 protein] |
CTD |
PMID:9109525 |
|
NCBI chr17:10,540,440...10,544,971
Ensembl chr17:10,540,558...10,545,002
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Lanthanum inhibits the reaction [3-N-methylspiperone binds to DRD2 protein] |
CTD |
PMID:9109525 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
Lanthanum results in decreased expression of EGR1 mRNA |
CTD |
PMID:21695898 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Lanthanum results in decreased expression of FOS mRNA |
CTD |
PMID:21695898 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabrb3 |
gamma-aminobutyric acid type A receptor subunit beta 3 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:108,296,124...108,698,961
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
ISO |
[delta-hexachlorocyclohexane co-treated with Lanthanum] promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]]; Lanthanum promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB3 protein binds to GABRG2 protein]] |
CTD |
PMID:9316872 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
Lanthanum binds to and results in increased expression of HSPA5 protein |
CTD |
PMID:18773883 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [IGF2 protein results in increased import of Calcium] |
CTD |
PMID:2442157 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Ins2 |
insulin 2 |
decreases response to substance |
ISO |
Lanthanum results in decreased susceptibility to INS protein |
CTD |
PMID:22031853 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Lanthanum results in decreased expression of JUN mRNA |
CTD |
PMID:21695898 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Lanthanum promotes the reaction [LEP protein results in increased transport of Calcium] |
CTD |
PMID:20107083 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
decreases activity |
ISO |
Lanthanum results in decreased activity of TRPC6 protein |
CTD |
PMID:11179201 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
Lanthanum inhibits the reaction [TRPM6 protein affects the reaction [1-oleoyl-2-acetylglycerol results in increased transport of Calcium]] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
G |
Trpv6 |
transient receptor potential cation channel, subfamily V, member 6 |
multiple interactions increases uptake |
ISO |
Lanthanum inhibits the reaction [TRPV6 protein results in increased uptake of Calcium] TRPV6 protein results in increased uptake of Lanthanum |
CTD |
PMID:21146870 |
|
NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:70,507,348...70,523,017
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
ISO |
Lanthanum results in increased expression of XBP1 mRNA alternative form |
CTD |
PMID:18773883 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Alb |
albumin |
increases expression |
ISO |
lanthanum chloride results in increased expression of ALB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of ALOX12 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of AOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Apoe |
apolipoprotein E |
increases expression multiple interactions |
ISO |
lanthanum chloride results in increased expression of APOE mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of APOE mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
EXP |
lanthanum chloride results in increased expression of ATG12 protein |
CTD |
PMID:35090998 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
EXP |
lanthanum chloride results in increased expression of ATG7 protein |
CTD |
PMID:35090998 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
B2m |
beta-2 microglobulin |
increases expression |
ISO |
lanthanum chloride results in increased expression of B2M mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Bcap31 |
B-cell receptor-associated protein 31 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of BCAP31 protein |
CTD |
PMID:35090998 |
|
NCBI chr X:151,397,567...151,429,666
Ensembl chr X:151,397,576...151,428,506
|
|
G |
Becn1 |
beclin 1 |
increases expression |
EXP |
lanthanum chloride results in increased expression of BECN1 protein |
CTD |
PMID:35090998 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Camk4 |
calcium/calmodulin-dependent protein kinase IV |
decreases phosphorylation |
EXP |
lanthanum chloride results in decreased phosphorylation of CAMK4 protein |
CTD |
PMID:19643171 |
|
NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487
|
|
G |
Casp3 |
caspase 3 |
increases expression |
EXP |
lanthanum chloride results in increased expression of CASP3 protein |
CTD |
PMID:21793157 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases expression |
EXP |
lanthanum chloride results in increased expression of CASP9 protein |
CTD |
PMID:21793157 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of CAT mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of CCL5 mRNA lanthanum chloride results in increased expression of CCL5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccs |
copper chaperone for superoxide dismutase |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] affects the expression of CCS mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:202,113,792...202,134,931
Ensembl chr 1:202,113,804...202,134,915
|
|
G |
Cygb |
cytoglobin |
multiple interactions affects expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of CYGB mRNA lanthanum chloride affects the expression of CYGB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Duox1 |
dual oxidase 1 |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX1 mRNA lanthanum chloride results in increased expression of DUOX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,260,526...109,295,588
Ensembl chr 3:109,262,397...109,295,563
|
|
G |
Duox2 |
dual oxidase 2 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of DUOX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:109,223,809...109,247,023
Ensembl chr 3:109,226,924...109,245,902
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression multiple interactions |
ISO |
lanthanum chloride results in increased expression of DUSP1 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of DUSP1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Egr1 |
early growth response 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of EGR1 mRNA; lanthanum chloride results in decreased expression of EGR1 protein |
CTD |
PMID:19643171 PMID:21624330 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of EPHX2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Epx |
eosinophil peroxidase |
increases expression |
ISO |
lanthanum chloride results in increased expression of EPX mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952
|
|
G |
Fis1 |
fission, mitochondrial 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of FIS1 protein |
CTD |
PMID:35090998 |
|
NCBI chr12:19,708,560...19,723,392
Ensembl chr12:19,708,558...19,723,377
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of FOS protein |
CTD |
PMID:19643171 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Foxm1 |
forkhead box M1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of FOXM1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of GAPDH mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression multiple interactions decreases expression |
ISO |
lanthanum chloride results in increased expression of GCLC mRNA; lanthanum chloride results in increased expression of GCLC protein [cerous chloride co-treated with lanthanum chloride] results in increased expression of GCLC mRNA lanthanum chloride results in decreased expression of GCLC protein |
CTD |
PMID:24142884 PMID:28954213 PMID:33098623 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gls |
glutaminase |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of GLS |
CTD |
PMID:29353069 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Glul |
glutamate-ammonia ligase |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of GLUL |
CTD |
PMID:29353069 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression multiple interactions |
ISO |
lanthanum chloride results in increased expression of GPX3 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of GPX3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Gpx7 |
glutathione peroxidase 7 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of GPX7 mRNA lanthanum chloride results in decreased expression of GPX7 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:123,144,331...123,153,004
|
|
G |
Grin1 |
glutamate ionotropic receptor NMDA type subunit 1 |
increases expression |
EXP |
lanthanum chloride results in increased expression of GRIN1 |
CTD |
PMID:29353069 |
|
NCBI chr 3:8,103,680...8,130,603
Ensembl chr 3:8,103,680...8,130,603
|
|
G |
Grin2a |
glutamate ionotropic receptor NMDA type subunit 2A |
increases expression |
EXP |
lanthanum chloride results in increased expression of GRIN2A |
CTD |
PMID:29353069 |
|
NCBI chr10:5,629,683...6,053,262
Ensembl chr10:5,631,369...6,044,637
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
increases expression |
EXP |
lanthanum chloride results in increased expression of GRIN2B |
CTD |
PMID:29353069 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of GSTZ1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions decreases expression increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of HMOX1 mRNA lanthanum chloride results in decreased expression of HMOX1 protein lanthanum chloride results in increased expression of HMOX1 mRNA; lanthanum chloride results in increased expression of HMOX1 protein lanthanum chloride results in decreased expression of HMOX1 mRNA |
CTD |
PMID:24142884 PMID:28954213 PMID:33098623 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of JUN mRNA; lanthanum chloride results in decreased expression of JUN protein |
CTD |
PMID:21624330 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnip1 |
potassium voltage-gated channel interacting protein 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of KCNIP1 protein |
CTD |
PMID:35090998 |
|
NCBI chr10:18,219,519...18,588,833
Ensembl chr10:18,219,519...18,589,045
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
increases expression |
ISO |
lanthanum chloride results in increased expression of KEAP1 protein |
CTD |
PMID:33098623 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
increases expression |
EXP |
lanthanum chloride results in increased expression of LAMP2 protein |
CTD |
PMID:35090998 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Ldha |
lactate dehydrogenase A |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of LDHA mRNA; lanthanum chloride results in decreased expression of LDHA protein |
CTD |
PMID:29264619 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Ldhb |
lactate dehydrogenase B |
increases expression |
EXP |
lanthanum chloride results in increased expression of LDHB mRNA; lanthanum chloride results in increased expression of LDHB protein |
CTD |
PMID:29264619 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lpo |
lactoperoxidase |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of LPO mRNA lanthanum chloride results in increased expression of LPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,606,950...72,626,220
Ensembl chr10:72,606,944...72,626,535
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
EXP ISO |
lanthanum chloride results in increased expression of MAP1LC3B protein modified form |
CTD |
PMID:35090998 PMID:38253231 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mb |
myoglobin |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of MB mRNA lanthanum chloride results in increased expression of MB mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383
|
|
G |
Mbl2 |
mannose binding lectin 2 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of MBL2 mRNA lanthanum chloride results in decreased expression of MBL2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:228,016,439...228,024,736
|
|
G |
Mfn1 |
mitofusin 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of MFN1 protein |
CTD |
PMID:35090998 |
|
NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
|
|
G |
Mfn2 |
mitofusin 2 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of MFN2 protein |
CTD |
PMID:35090998 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mpo |
myeloperoxidase |
affects expression |
ISO |
lanthanum chloride affects the expression of MPO mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mpv17 |
mitochondrial inner membrane protein MPV17 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of MPV17 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:25,221,668...25,236,241
Ensembl chr 6:25,222,896...25,236,244
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of MTOR protein modified form |
CTD |
PMID:35090998 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of NCF2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
lanthanum chloride results in increased expression of NFE2L2 mRNA; lanthanum chloride results in increased expression of NFE2L2 protein |
CTD |
PMID:24142884 PMID:33098623 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
lanthanum chloride results in increased expression of NOS2 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of NOS2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
increases expression |
EXP |
lanthanum chloride results in increased expression of NOX4 protein |
CTD |
PMID:35090998 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Npm1 |
nucleophosmin 1 |
multiple interactions |
ISO |
lanthanum chloride results in decreased expression of and affects the localization of NPM1 protein |
CTD |
PMID:38253231 |
|
NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
decreases expression |
ISO |
lanthanum chloride results in decreased expression of NQO1 protein |
CTD |
PMID:33098623 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nudt1 |
nudix hydrolase 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of NUDT1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr12:14,302,514...14,309,559
Ensembl chr12:14,302,694...14,305,826
|
|
G |
Pcna |
proliferating cell nuclear antigen |
affects expression multiple interactions |
ISO |
lanthanum chloride affects the expression of PCNA protein [cerous chloride co-treated with lanthanum chloride] affects the expression of PCNA protein |
CTD |
PMID:28954213 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PRDX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx5 |
peroxiredoxin 5 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of PRDX5 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:204,099,826...204,103,589
Ensembl chr 1:204,099,826...204,114,268
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PREX1 mRNA lanthanum chloride results in decreased expression of PREX1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688
|
|
G |
Pxdn |
peroxidasin |
multiple interactions decreases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of PXDN mRNA lanthanum chloride results in decreased expression of PXDN mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 6:46,580,749...46,658,345
Ensembl chr 6:46,580,761...46,658,345
|
|
G |
Pygb |
glycogen phosphorylase B |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of PYGB mRNA; lanthanum chloride results in decreased expression of PYGB protein |
CTD |
PMID:29264619 |
|
NCBI chr 3:139,611,724...139,658,521
Ensembl chr 3:139,611,749...139,663,553
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
increases expression |
EXP |
lanthanum chloride results in increased expression of RAB7A protein |
CTD |
PMID:35090998 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
[lanthanum chloride co-treated with Cisplatin] results in increased expression of RAD51 protein |
CTD |
PMID:38253231 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rmdn3 |
regulator of microtubule dynamics 3 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of RMDN3 protein |
CTD |
PMID:35090998 |
|
NCBI chr 3:106,125,961...106,146,568
Ensembl chr 3:106,125,951...106,146,586
|
|
G |
Scara3 |
scavenger receptor class A, member 3 |
increases expression |
ISO |
lanthanum chloride results in increased expression of SCARA3 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr15:40,139,873...40,172,866
Ensembl chr15:40,140,161...40,172,894
|
|
G |
Selenop |
selenoprotein P |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SELENOP mRNA lanthanum chloride results in increased expression of SELENOP mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852
|
|
G |
Sirt2 |
sirtuin 2 |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SIRT2 mRNA lanthanum chloride results in increased expression of SIRT2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC16A1 mRNA; lanthanum chloride results in decreased expression of SLC16A1 protein |
CTD |
PMID:29264619 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc16a3 |
solute carrier family 16 member 3 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC16A3 mRNA; lanthanum chloride results in decreased expression of SLC16A3 protein |
CTD |
PMID:29264619 |
|
NCBI chr10:106,212,679...106,222,564
Ensembl chr10:106,212,778...106,222,562
|
|
G |
Slc16a7 |
solute carrier family 16 member 7 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC16A7 mRNA; lanthanum chloride results in decreased expression of SLC16A7 protein |
CTD |
PMID:29264619 |
|
NCBI chr 7:61,043,667...61,211,547
Ensembl chr 7:61,051,167...61,154,994
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC1A2 |
CTD |
PMID:29353069 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc1a3 |
solute carrier family 1 member 3 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC1A3 |
CTD |
PMID:29353069 |
|
NCBI chr 2:57,755,495...57,830,605
Ensembl chr 2:57,755,497...57,830,605
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of SLC2A1 mRNA; lanthanum chloride results in decreased expression of SLC2A1 protein |
CTD |
PMID:29264619 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SOD2 mRNA lanthanum chloride results in increased expression of SOD2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO EXP |
[cerous chloride co-treated with lanthanum chloride] results in increased expression of SQSTM1 mRNA lanthanum chloride results in decreased expression of SQSTM1 protein |
CTD |
PMID:28954213 PMID:35090998 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression multiple interactions |
ISO |
lanthanum chloride results in increased expression of SRXN1 mRNA [cerous chloride co-treated with lanthanum chloride] results in increased expression of SRXN1 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Stk25 |
serine/threonine kinase 25 |
multiple interactions |
ISO |
[cerous chloride co-treated with lanthanum chloride] results in decreased expression of STK25 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 9:94,161,834...94,174,095
Ensembl chr 9:94,161,836...94,174,244
|
|
G |
Stx17 |
syntaxin 17 |
increases expression |
EXP |
lanthanum chloride results in increased expression of STX17 protein |
CTD |
PMID:35090998 |
|
NCBI chr 5:62,446,138...62,506,108
Ensembl chr 5:62,446,187...62,504,451
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression multiple interactions |
ISO |
lanthanum chloride results in decreased expression of UCP2 mRNA [cerous chloride co-treated with lanthanum chloride] affects the expression of UCP2 mRNA |
CTD |
PMID:28954213 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
increases expression decreases expression |
EXP |
lanthanum chloride results in increased expression of ULK1 protein lanthanum chloride results in decreased expression of ULK1 protein modified form |
CTD |
PMID:35090998 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vapb |
VAMP associated protein B and C |
decreases expression |
EXP |
lanthanum chloride results in decreased expression of VAPB protein |
CTD |
PMID:35090998 |
|
NCBI chr 3:162,535,974...162,578,747
Ensembl chr 3:162,535,905...162,573,763
|
|
|
G |
Agl |
amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of AGL mRNA motexafin gadolinium results in decreased expression of AGL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:204,705,053...204,760,966
Ensembl chr 2:204,705,053...204,760,828
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of ALDH5A1 mRNA] motexafin gadolinium results in increased expression of ALDH5A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ALDH6A1 mRNA Zinc Acetate inhibits the reaction [motexafin gadolinium results in decreased expression of ALDH6A1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Arhgap17 |
Rho GTPase activating protein 17 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ARHGAP17 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ARHGAP17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:177,807,579...177,897,027
Ensembl chr 1:177,807,583...177,896,854
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of ATF3 mRNA] motexafin gadolinium results in increased expression of ATF3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of ATM mRNA] motexafin gadolinium results in increased expression of ATM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ATR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ATR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BACH1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BACH1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bag3 |
BAG cochaperone 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of BAG3 mRNA] motexafin gadolinium results in increased expression of BAG3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of BBC3 protein] |
CTD |
PMID:20530418 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of BIRC5 mRNA] motexafin gadolinium results in increased expression of BIRC5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of BNIP3L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of BNIP3L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Canx |
calnexin |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CANX mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CANX mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp3 |
caspase 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CASP3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CASP3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cbfb |
core-binding factor subunit beta |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CBFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CBFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751
|
|
G |
Ccnj |
cyclin J |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CCNJ mRNA motexafin gadolinium results in decreased expression of CCNJ mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:239,659,588...239,677,367
|
|
G |
Cdc16 |
cell division cycle 16 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC16 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC16 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:75,773,026...75,796,586
Ensembl chr16:75,773,028...75,796,550
|
|
G |
Cdc25c |
cell division cycle 25C |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC25C mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDC25C mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc27 |
cell division cycle 27 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDC27 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of CDC27 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736
|
|
G |
Cdc5l |
cell division cycle 5-like |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDC5L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDC5L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:15,564,949...15,603,453
Ensembl chr 9:15,564,767...15,603,450
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CDCA2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDCA2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdk19 |
cyclin-dependent kinase 19 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of CDK19 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:43,770,409...43,910,629
Ensembl chr20:43,770,409...43,910,628
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of CDK2 mRNA] motexafin gadolinium results in increased expression of CDK2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CDKN1B mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CDKN1B mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of CTH mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CTH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Cul3 |
cullin 3 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of CUL3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CUL3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
|
|
G |
Cyb5r1 |
cytochrome b5 reductase 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of CYB5R1 mRNA motexafin gadolinium results in increased expression of CYB5R1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
|
|
G |
Dapk3 |
death-associated protein kinase 3 |
multiple interactions decreases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DAPK3 mRNA] motexafin gadolinium results in decreased expression of DAPK3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:8,524,182...8,532,552
Ensembl chr 7:8,524,183...8,532,558
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DDIT3 mRNA] motexafin gadolinium results in increased expression of DDIT3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DDIT4 mRNA motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of DDIT4 mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of DDIT4 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dedd2 |
death effector domain containing 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of DEDD2 mRNA] motexafin gadolinium results in increased expression of DEDD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of DFFB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of DFFB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in decreased expression of DNAJB1 mRNA] motexafin gadolinium results in increased expression of DNAJB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of DNAJB6 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of DNAJC3 mRNA] motexafin gadolinium results in increased expression of DNAJC3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F1 mRNA motexafin gadolinium results in increased expression of E2F1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f3 |
E2F transcription factor 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of E2F3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of E2F3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:34,601,756...34,679,139
Ensembl chr17:34,601,830...34,676,253
|
|
G |
Egln1 |
egl-9 family hypoxia-inducible factor 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of EGLN1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of EGLN1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:52,867,900...52,907,308
Ensembl chr19:52,869,486...52,907,777
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of ELP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of ELP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:71,453,338...71,505,833
Ensembl chr 5:71,456,310...71,505,762
|
|
G |
Eno1 |
enolase 1 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of ENO1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FADD mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FADD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Faim |
Fas apoptotic inhibitory molecule |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of FAIM mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of FAIM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:99,543,877...99,569,499
Ensembl chr 8:99,542,405...99,560,562
|
|
G |
Fam162a |
family with sequence similarity 162, member A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FAM162A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FAM162A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of FASN mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Foxo3 |
forkhead box O3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of FOXO3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of FOXO3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GCLM mRNA motexafin gadolinium results in increased expression of GCLM mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gls |
glutaminase |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of GLS mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GLS mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900
|
|
G |
Gpr146 |
G protein-coupled receptor 146 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPR146 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:15,251,936...15,267,217
Ensembl chr12:15,251,813...15,267,206
|
|
G |
Gpt2 |
glutamic--pyruvic transaminase 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GPT2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:21,526,800...21,561,314
Ensembl chr19:21,517,621...21,560,610
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of GPX1 mRNA] |
CTD |
PMID:20530418 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsr |
glutathione-disulfide reductase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of GSR mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of GSR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gtf3c2 |
general transcription factor IIIC subunit 2 |
increases expression |
ISO |
motexafin gadolinium results in increased expression of GTF3C2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HBP1 mRNA motexafin gadolinium results in increased expression of HBP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:48,529,633...48,555,775
Ensembl chr 6:48,529,372...48,555,787
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HIF1A protein motexafin gadolinium results in increased expression of HIF1A protein |
CTD |
PMID:16357179 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hilpda |
hypoxia inducible lipid droplet-associated |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HILPDA mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HILPDA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:57,871,088...57,874,048
Ensembl chr 4:57,871,110...57,874,557
|
|
G |
Hipk1 |
homeodomain interacting protein kinase 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HIPK1 mRNA] motexafin gadolinium results in increased expression of HIPK1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:191,248,817...191,299,787
Ensembl chr 2:191,248,817...191,298,902
|
|
G |
Hltf |
helicase-like transcription factor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of HLTF mRNA motexafin gadolinium results in decreased expression of HLTF mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:102,549,724...102,609,492
Ensembl chr 2:102,549,724...102,609,327
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression |
ISO |
[motexafin gadolinium co-treated with Zinc Acetate] results in increased expression of HMOX1 protein; motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HMOX1 mRNA] motexafin gadolinium results in increased expression of HMOX1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hrk |
harakiri, BCL2 interacting protein |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HRK mRNA motexafin gadolinium results in increased expression of HRK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:38,387,484...38,409,652
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSP90AB1 mRNA motexafin gadolinium results in increased expression of HSP90AB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1A mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPA1B mRNA]; Zinc Acetate promotes the reaction [motexafin gadolinium results in increased expression of HSPA1B mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa4 |
heat shock protein family A (Hsp70) member 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:37,408,025...37,449,080
Ensembl chr10:37,408,025...37,449,001
|
|
G |
Hspa4l |
heat shock protein family A (Hsp70) member 4 like |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPA4L mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of HSPA4L mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPB1 mRNA] motexafin gadolinium results in increased expression of HSPB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of HSPD1 mRNA] motexafin gadolinium results in increased expression of HSPD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of HSPH1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of HSPH1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
|
|
G |
Id2 |
inhibitor of DNA binding 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of ID2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of ID2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:41,740,556...41,742,393
Ensembl chr 6:41,728,946...41,744,400
|
|
G |
Ikbke |
inhibitor of nuclear factor kappa B kinase subunit epsilon |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IKBKE mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IKBKE mRNA |
CTD |
PMID:16357179 |
|
NCBI chr13:42,712,154...42,738,470
Ensembl chr13:42,712,159...42,737,143
|
|
G |
Irf2bp2 |
interferon regulatory factor 2 binding protein 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of IRF2BP2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of IRF2BP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:54,559,417...54,565,096
Ensembl chr19:54,560,128...54,566,642
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of JUND mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of JUND mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kdm3a |
lysine demethylase 3A |
increases expression |
ISO |
motexafin gadolinium results in increased expression of KDM3A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:103,630,907...103,675,073
Ensembl chr 4:103,630,908...103,675,073
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MDM2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MDM2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mob1a |
MOB kinase activator 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of MOB1A mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of MOB1A mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 4:115,831,581...115,848,561
Ensembl chr 4:115,831,551...115,848,561
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of MT1A mRNA |
CTD |
PMID:15867382 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049
|
|
G |
Mt1-ps3 |
metallothionein 1, pseudogene 3 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of MT1E mRNA motexafin gadolinium results in increased expression of MT1E mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr17:74,786,652...74,787,040
Ensembl chr17:74,786,654...74,787,135
|
|
G |
Mt2-ps1 |
metallothionein 2, pseudogene 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT1HL1 mRNA] motexafin gadolinium results in increased expression of MT1HL1 mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr20:3,159,037...3,159,409
Ensembl chr 5:119,728,811...119,730,073
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions increases expression |
ISO |
motexafin gadolinium promotes the reaction [Zinc Acetate results in increased expression of MT2A mRNA] motexafin gadolinium results in increased expression of MT2A mRNA |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of MYD88 mRNA motexafin gadolinium results in decreased expression of MYD88 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nadk |
NAD kinase |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NADK mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NADK mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322
|
|
G |
Nf1 |
neurofibromin 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of NF1 mRNA motexafin gadolinium results in increased expression of NF1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:64,306,027...64,539,112
Ensembl chr10:64,306,301...64,536,658
|
|
G |
Nisch |
nischarin |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of NISCH mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:6,364,370...6,400,675
Ensembl chr16:6,364,374...6,400,668
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of NR1D2 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of NR1D2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of P4HB mRNA] motexafin gadolinium results in increased expression of P4HB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Pdcd11 |
programmed cell death 11 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PDCD11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:245,980,840...246,021,999
Ensembl chr 1:245,980,880...246,021,999
|
|
G |
Pdcd4 |
programmed cell death 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PDCD4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PDCD4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275
|
|
G |
Pdcd5 |
programmed cell death 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PDCD5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PDCD5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:88,305,869...88,311,200
Ensembl chr 1:88,305,869...88,311,200
|
|
G |
Pfkfb3 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr17:66,983,629...67,064,702
Ensembl chr17:66,983,686...67,063,125
|
|
G |
Pfkfb4 |
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PFKFB4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PFKFB4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:109,643,558...109,687,006
Ensembl chr 8:109,643,937...109,685,634
|
|
G |
Pgk1 |
phosphoglycerate kinase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PGK1 mRNA motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PGK1 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr X:71,271,454...71,287,429
Ensembl chr X:71,271,440...71,287,418
|
|
G |
Phtf2 |
putative homeodomain transcription factor 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PHTF2 mRNA] motexafin gadolinium results in increased expression of PHTF2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:14,215,190...14,330,549
Ensembl chr 4:14,215,263...14,330,513
|
|
G |
Pias1 |
protein inhibitor of activated STAT, 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of PIAS1 mRNA] motexafin gadolinium results in increased expression of PIAS1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:63,338,150...63,451,670
Ensembl chr 8:63,338,150...63,438,905
|
|
G |
Pik3ip1 |
phosphoinositide-3-kinase interacting protein 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of PIK3IP1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PIK3IP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:78,204,668...78,216,616
Ensembl chr14:78,204,053...78,216,608
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PMAIP1 mRNA motexafin gadolinium results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Prkacb |
protein kinase cAMP-activated catalytic subunit beta |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of PRKACB mRNA motexafin gadolinium results in increased expression of PRKACB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:235,636,878...235,726,928
Ensembl chr 2:235,636,885...235,726,198
|
|
G |
Prkcd |
protein kinase C, delta |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKCD mRNA |
CTD |
PMID:16357179 |
|
NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352
|
|
G |
Prkd2 |
protein kinase D2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of PRKD2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:77,513,625...77,542,386
Ensembl chr 1:77,513,986...77,542,376
|
|
G |
Prkdc |
protein kinase, DNA-activated, catalytic subunit |
increases expression |
ISO |
motexafin gadolinium results in increased expression of PRKDC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952
|
|
G |
Ptrh2 |
peptidyl-tRNA hydrolase 2 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of PTRH2 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of PTRH2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:71,505,113...71,515,297
Ensembl chr10:71,504,956...71,515,398
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of RB1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RB1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rcbtb2 |
RCC1 and BTB domain containing protein 2 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of RCBTB2 mRNA motexafin gadolinium results in decreased expression of RCBTB2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:48,319,809...48,364,441
Ensembl chr15:48,323,866...48,383,750
|
|
G |
Relb |
RELB proto-oncogene, NF-kB subunit |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of RELB mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of RELB mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:79,257,738...79,285,490
Ensembl chr 1:79,257,725...79,285,507
|
|
G |
Rnf19b |
ring finger protein 19B |
increases expression |
ISO |
motexafin gadolinium results in increased expression of RNF19B mRNA |
CTD |
PMID:15867382 |
|
NCBI chr 5:141,406,085...141,431,376
Ensembl chr 5:141,406,118...141,431,380
|
|
G |
Samtor |
S-adenosylmethionine sensor upstream of mTORC1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SAMTOR mRNA motexafin gadolinium results in increased expression of SAMTOR mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:41,881,630...41,945,472
Ensembl chr 4:41,879,993...41,945,539
|
|
G |
Selenow |
selenoprotein W |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SELENOW mRNA motexafin gadolinium results in increased expression of SELENOW mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:76,599,441...76,604,514
Ensembl chr 1:76,598,779...76,604,724 Ensembl chr 1:76,598,779...76,604,724
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions increases expression |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA; [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SESN2 mRNA; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SESN2 mRNA] motexafin gadolinium results in increased expression of SESN2 mRNA |
CTD |
PMID:16357179 PMID:20530418 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Slc16a1 |
solute carrier family 16 member 1 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC16A1 mRNA] motexafin gadolinium results in increased expression of SLC16A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611
|
|
G |
Slc16a6 |
solute carrier family 16, member 6 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC16A6 mRNA motexafin gadolinium results in increased expression of SLC16A6 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:94,424,377...94,447,482
Ensembl chr10:94,426,244...94,448,779
|
|
G |
Slc1a4 |
solute carrier family 1 member 4 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC1A4 mRNA] motexafin gadolinium results in increased expression of SLC1A4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418
|
|
G |
Slc30a1 |
solute carrier family 30 member 1 |
multiple interactions increases expression |
ISO |
[Zinc co-treated with motexafin gadolinium] results in increased expression of SLC30A1 mRNA; motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC30A1 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC30A1 mRNA] |
CTD |
PMID:15867382 PMID:16357179 |
|
NCBI chr13:103,491,037...103,494,910
Ensembl chr13:103,491,037...103,494,910
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of SLC38A2 mRNA]; Zinc Acetate affects the reaction [motexafin gadolinium results in increased expression of SLC38A2 mRNA] |
CTD |
PMID:16357179 |
|
NCBI chr 7:127,851,267...127,863,482
Ensembl chr 7:127,851,267...127,863,436
|
|
G |
Slc39a10 |
solute carrier family 39 member 10 |
multiple interactions affects expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A10 mRNA motexafin gadolinium affects the expression of SLC39A10 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:54,876,141...54,960,325
|
|
G |
Slc39a14 |
solute carrier family 39 member 14 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A14 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC39A14 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr15:45,376,806...45,423,549
Ensembl chr15:45,376,917...45,423,524
|
|
G |
Slc39a9 |
solute carrier family 39, member 9 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC39A9 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC39A9 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 6:100,291,537...100,330,419
Ensembl chr 6:100,291,573...100,330,408
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC3A2 mRNA motexafin gadolinium results in increased expression of SLC3A2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc43a1 |
solute carrier family 43 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of SLC43A1 mRNA motexafin gadolinium results in increased expression of SLC43A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:69,920,649...69,946,768
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
multiple interactions increases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A1 mRNA motexafin gadolinium results in increased expression of SLC7A1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of SLC7A11 mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of SLC7A11 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smarca4 |
SWI/SNF related BAF chromatin remodeling complex subunit ATPase 4 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA4 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA4 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 8:20,167,717...20,258,975
Ensembl chr 8:20,167,717...20,258,975
|
|
G |
Smarca5 |
SNF2 related chromatin remodeling ATPase 5 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of SMARCA5 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of SMARCA5 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr19:27,271,918...27,304,594
Ensembl chr19:27,271,148...27,304,594
|
|
G |
Tagap |
T-cell activation RhoGTPase activating protein |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TAGAP mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TAGAP mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 1:47,170,725...47,179,705
Ensembl chr 1:47,170,725...47,179,792
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
ISO |
motexafin gadolinium affects the reaction [Zinc Acetate results in increased expression of TFRC mRNA] motexafin gadolinium results in increased expression of TFRC mRNA |
CTD |
PMID:16357179 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tnfaip8 |
TNF alpha induced protein 8 |
decreases expression multiple interactions |
ISO |
motexafin gadolinium results in decreased expression of TNFAIP8 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFAIP8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr18:43,183,854...43,299,512
Ensembl chr18:43,183,916...43,299,517
|
|
G |
Tnfrsf17 |
TNF receptor superfamily member 17 |
multiple interactions decreases expression |
ISO |
[Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TNFRSF17 mRNA motexafin gadolinium results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr10:4,301,023...4,306,889
Ensembl chr10:4,301,038...4,306,788
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TNFRSF1A mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TNFRSF1A mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfsf8 |
TNF superfamily member 8 |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of TNFSF8 mRNA] motexafin gadolinium results in increased expression of TNFSF8 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421
|
|
G |
Tnip2 |
TNFAIP3 interacting protein 2 |
decreases expression |
ISO |
motexafin gadolinium results in decreased expression of TNIP2 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr14:76,228,350...76,245,553
Ensembl chr14:76,228,371...76,275,265
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein; Acetylcysteine inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein]; nutlin 3 inhibits the reaction [[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of TP53 protein] |
CTD |
PMID:20530418 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TRIB3 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TRIB3 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of TXNRD1 mRNA [Zinc Acetate co-treated with motexafin gadolinium] results in increased expression of TXNRD1 mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
motexafin gadolinium results in increased expression of VEGFA mRNA [Zinc Acetate co-treated with motexafin gadolinium] affects the expression of VEGFA mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vhl |
von Hippel-Lindau tumor suppressor |
multiple interactions increases expression |
ISO |
motexafin gadolinium inhibits the reaction [Zinc Acetate results in increased expression of VHL mRNA] motexafin gadolinium results in increased expression of VHL mRNA |
CTD |
PMID:16357179 |
|
NCBI chr 4:146,772,483...146,779,376
Ensembl chr 4:146,772,468...146,779,377
|
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
ISO |
Neodymium inhibits the reaction [CACNA1G protein results in increased transport of Barium] |
CTD |
PMID:12163980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
decreases phosphorylation increases expression |
ISO |
Neodymium results in decreased phosphorylation of HSPB1 protein Neodymium results in increased expression of HSPB1 mRNA; Neodymium results in increased expression of HSPB1 protein |
CTD |
PMID:20332019 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Psmb2 |
proteasome 20S subunit beta 2 |
decreases expression |
ISO |
Neodymium results in decreased expression of PSMB2 protein |
CTD |
PMID:20332019 |
|
NCBI chr 5:138,970,564...139,002,715
Ensembl chr 5:138,970,533...139,021,137
|
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
increases mutagenesis |
EXP |
Plutonium results in increased mutagenesis of HRAS gene |
CTD |
PMID:9255578 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
|
G |
Aadat |
aminoadipate aminotransferase |
affects expression |
ISO |
Uranium affects the expression of AADAT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr16:29,509,392...29,544,332
Ensembl chr16:29,509,394...29,544,332
|
|
G |
Aanat |
aralkylamine N-acetyltransferase |
affects expression |
ISO |
Uranium affects the expression of AANAT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:101,827,072...101,831,805
Ensembl chr10:101,827,301...101,831,801
|
|
G |
Aasdhppt |
aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase |
affects expression |
ISO |
Uranium affects the expression of AASDHPPT mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 8:1,453,226...1,463,990
Ensembl chr 8:1,452,282...1,463,966
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
EXP |
[Acetaminophen co-treated with Uranium analog] results in increased expression of ABCC2 mRNA; Uranium analog promotes the reaction [Acetaminophen results in increased expression of ABCC2 mRNA] |
CTD |
PMID:17126469 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
affects expression |
ISO |
Uranium affects the expression of ABCC8 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Abcf2 |
ATP binding cassette subfamily F member 2 |
affects expression |
ISO |
Uranium affects the expression of ABCF2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606
|
|
G |
Acat2 |
acetyl-CoA acetyltransferase 2 |
affects expression |
ISO |
Uranium affects the expression of ACAT2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
increases expression multiple interactions increases secretion |
EXP |
Uranium results in increased expression of ACP5 protein GHRL protein inhibits the reaction [Uranium results in increased secretion of ACP5 protein] |
CTD |
PMID:16436523 PMID:29477364 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Actb |
actin, beta |
affects expression |
ISO |
Uranium affects the expression of ACTB mRNA; Uranium affects the expression of ACTB protein |
CTD |
PMID:15672453 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actr2 |
actin related protein 2 |
affects expression |
ISO |
Uranium affects the expression of ACTR2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524
|
|
G |
Adar |
adenosine deaminase, RNA-specific |
affects expression |
ISO |
Uranium affects the expression of ADAR mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 2:175,138,391...175,178,280
Ensembl chr 2:175,138,403...175,178,282
|
|
G |
Adnp |
activity-dependent neuroprotector homeobox |
affects expression |
ISO |
Uranium affects the expression of ADNP mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:156,886,921...156,921,500
Ensembl chr 3:156,891,381...156,917,312
|
|
G |
Akap1 |
A-kinase anchoring protein 1 |
affects expression |
ISO |
Uranium affects the expression of AKAP1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:73,621,021...73,654,123
Ensembl chr10:73,621,883...73,653,896
|
|
G |
Akirin1 |
akirin 1 |
increases expression |
ISO |
Uranium results in increased expression of AKIRIN1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 5:135,989,378...136,004,782
Ensembl chr 5:135,989,465...136,004,762
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
affects expression |
ISO |
Uranium affects the expression of AKR1C3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions decreases secretion |
EXP |
GHRL protein inhibits the reaction [Uranium results in decreased secretion of ALPL protein] |
CTD |
PMID:29477364 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
affects expression |
ISO |
Uranium affects the expression of APBB1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects expression |
ISO |
Uranium affects the expression of APC mRNA |
CTD |
PMID:15672453 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Aplnr |
apelin receptor |
decreases expression |
EXP |
Uranium results in decreased expression of APLNR mRNA |
CTD |
PMID:37270086 |
|
NCBI chr 3:70,217,407...70,221,052
Ensembl chr 3:70,217,385...70,221,050
|
|
G |
App |
amyloid beta precursor protein |
affects expression |
ISO |
Uranium affects the expression of APP mRNA |
CTD |
PMID:15672453 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
affects expression |
ISO |
Uranium affects the expression of APPL1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Ar |
androgen receptor |
decreases expression |
EXP |
Uranium analog results in decreased expression of AR mRNA |
CTD |
PMID:27544493 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Armc9 |
armadillo repeat containing 9 |
increases expression |
ISO |
Uranium results in increased expression of ARMC9 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 9:86,802,791...86,928,611
Ensembl chr 9:86,802,868...86,928,860
|
|
G |
Asap2 |
ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 |
affects expression |
ISO |
Uranium affects the expression of ASAP2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 6:40,658,201...40,821,017
Ensembl chr 6:40,657,880...40,820,975
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
increases expression |
EXP |
Uranium results in increased expression of ASCL1 mRNA |
CTD |
PMID:27639536 |
|
NCBI chr 7:21,903,136...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
affects expression |
ISO |
Uranium affects the expression of ATP6V1A mRNA |
CTD |
PMID:15672453 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp9b |
ATPase phospholipid transporting 9B (putative) |
affects expression |
ISO |
Uranium affects the expression of ATP9B mRNA |
CTD |
PMID:15672453 |
|
NCBI chr18:74,176,863...74,368,993
Ensembl chr18:74,176,863...74,368,953
|
|
G |
Atxn10 |
ataxin 10 |
affects expression |
ISO |
Uranium affects the expression of ATXN10 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 7:116,441,768...116,565,093
Ensembl chr 7:116,441,613...116,565,087
|
|
G |
B2m |
beta-2 microglobulin |
affects expression |
ISO |
Uranium affects the expression of B2M mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Baalc |
BAALC binder of MAP3K1 and KLF4 |
affects expression |
ISO |
Uranium affects the expression of BAALC mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 7:69,918,998...69,992,289
Ensembl chr 7:69,918,998...69,992,288
|
|
G |
Bace1 |
beta-secretase 1 |
affects expression |
ISO |
Uranium affects the expression of BACE mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression decreases secretion multiple interactions |
EXP ISO |
Uranium results in increased expression of BGLAP protein Uranium results in increased expression of BGLAP mRNA Uranium results in decreased secretion of BGLAP protein GHRL protein inhibits the reaction [Uranium results in decreased secretion of BGLAP protein] |
CTD |
PMID:16436523 PMID:29477364 PMID:31120128 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bgn |
biglycan |
affects expression |
ISO |
Uranium affects the expression of BGN mRNA |
CTD |
PMID:15672453 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Btf3 |
basic transcription factor 3 |
affects expression |
ISO |
Uranium affects the expression of BTF3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 2:29,659,764...29,666,898
Ensembl chr 2:29,659,231...29,666,879
|
|
G |
C12h12orf43 |
similar to human chromosome 12 open reading frame 43 |
affects expression |
ISO |
Uranium affects the expression of C12ORF43 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr12:41,672,089...41,677,722
Ensembl chr12:41,672,114...41,677,714
|
|
G |
Calb1 |
calbindin 1 |
decreases expression |
EXP |
Uranium results in decreased expression of CALB1 mRNA |
CTD |
PMID:17118558 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Calm2 |
calmodulin 2 |
affects expression |
ISO |
Uranium affects the expression of CALM2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287 Ensembl chr15:7,091,567...7,104,287
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
affects expression |
ISO |
Uranium affects the expression of CAMK2D mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178
|
|
G |
Canx |
calnexin |
affects expression |
ISO |
Uranium affects the expression of CANX mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:34,623,865...34,656,866
Ensembl chr10:34,625,191...34,656,821
|
|
G |
Casp3 |
caspase 3 |
increases activity increases expression multiple interactions |
EXP |
Uranium results in increased activity of CASP3 protein Uranium results in increased expression of CASP3 protein EIF2AK3 protein promotes the reaction [Uranium results in increased expression of CASP3 protein]; GHRL protein inhibits the reaction [Uranium results in increased activity of CASP3 protein]; THBS1 protein inhibits the reaction [Uranium results in increased expression of CASP3 protein] |
CTD |
PMID:29477364 PMID:37270086 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cbfa2t2 |
CBFA2/RUNX1 partner transcriptional co-repressor 2 |
affects expression |
ISO |
Uranium affects the expression of CBFA2T2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:142,936,945...143,043,205
Ensembl chr 3:142,936,985...143,043,197
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
EXP |
Uranium results in decreased expression of CCL2 mRNA; Uranium results in decreased expression of CCL2 protein |
CTD |
PMID:16854789 PMID:17566059 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Chchd5 |
coiled-coil-helix-coiled-coil-helix domain containing 5 |
increases expression |
ISO |
Uranium results in increased expression of CHCHD5 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:116,361,845...116,372,238
Ensembl chr 3:116,361,885...116,367,169
|
|
G |
Chrdl1 |
chordin-like 1 |
increases expression |
ISO |
Uranium results in increased expression of CHRDL1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr X:106,889,125...106,992,937
Ensembl chr X:106,889,125...106,992,921
|
|
G |
Churc1 |
churchill domain containing 1 |
increases expression |
ISO |
Uranium results in increased expression of CHURC1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 6:95,464,488...95,485,208
Ensembl chr 6:95,470,683...95,619,586
|
|
G |
Clint1 |
clathrin interactor 1 |
affects expression |
ISO |
Uranium affects the expression of CLINT1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:30,298,618...30,353,185
Ensembl chr10:30,298,704...30,353,063
|
|
G |
Clstn3 |
calsyntenin 3 |
affects expression |
ISO |
Uranium affects the expression of CLSTN3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cog7 |
component of oligomeric golgi complex 7 |
affects expression |
ISO |
Uranium affects the expression of COG7 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 1:176,489,795...176,549,455
Ensembl chr 1:176,489,791...176,549,455
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Uranium results in increased expression of COL1A1 mRNA |
CTD |
PMID:31120128 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cops3 |
COP9 signalosome subunit 3 |
affects expression |
ISO |
Uranium affects the expression of COPS3 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr10:44,618,115...44,652,807
Ensembl chr10:44,618,115...44,641,597
|
|
G |
Cp |
ceruloplasmin |
increases expression |
EXP |
Uranium results in increased expression of CP mRNA |
CTD |
PMID:18375546 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Crls1 |
cardiolipin synthase 1 |
affects expression |
ISO |
Uranium affects the expression of CRLS1 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr 3:120,119,822...120,138,674
Ensembl chr 3:120,119,852...120,138,655
|
|
G |
Crybb2 |
crystallin, beta B2 |
affects expression |
ISO |
Uranium affects the expression of CRYBB2 mRNA |
CTD |
PMID:15672453 |
|
NCBI chr12:43,569,747...43,579,671
Ensembl chr12:43,569,747...43,579,671
|
|
G |
Csde1 |
cold shock |